Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Chipscreen Biosciences

Drug Profile

Research programme: small molecule therapeutics - Chipscreen Biosciences

Alternative Names: CS 3158; CS 410; CS 510; CS-12192; CS-12328; CS-12629; CS-17919; CS-17938; CS00028; CS0220; CS0230; CS0240; CS0600; HDAC inhibitors - Chipscreen; Histone deacetylase inhibitors - Chipscreen Biosciences; Kinase inhibitors - Chipscreen Bioscience; VEGFR inhibitors - Chipscreen Biosciences

Latest Information Update: 27 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antineoplastics; Antirheumatics; Cardiovascular therapies; Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; Histone deacetylase inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Janus kinase 3 inhibitors; MAP kinase kinase kinase 5 inhibitors; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; Tryptophan oxygenase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Non-alcoholic steatohepatitis; Rheumatoid arthritis
  • No development reported Autoimmune disorders; Cardiovascular disorders; Neurodegenerative disorders; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 01 May 2019 Preclinical development in Rheumatoid arthritis is ongoing in China (Chipscreen Biosciences pipeline, May 2019)
  • 01 May 2019 Preclinical trials in Cancer in China before May 2019 (Chipscreen Biosciences pipeline, May 2019)
  • 01 May 2019 Preclinical trials in Non-alcoholic steatohepatitis in China before May 2019 (Chipscreen Biosciences pipeline, May 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top